Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Recruiting · NCT03618550 · Registry updated 2026-09-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-09-24 | NCT03618550 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 753 |
| Merck Sharp & Dohme LLC | 650 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Cancer Center (Data Collection Only) | Duarte | United States | 4 |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | United States | 189 |
| Memorial Sloan Kettering Bergen | Montvale | United States | 193 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Memorial Sloan Kettering Cancer Center @ Commack | Commack | United States | 7 |
| Memorial Sloan Kettering Monmouth | Middletown | United States | 206 |
| Memorial Sloan Kettering Nassau | Uniondale | United States | 193 |
| Memorial Sloan Kettering Westchester | Harrison | United States | 204 |
| Stanford University Medical Center | Stanford | United States | 4 |
| University of Miami (Data Collection Only) | Miami | United States | 4 |